Harnessing Artificial Intelligence to Optimize Long‐Term Maintenance Dosing for Antiretroviral‐Naive Adults with HIV‐1 Infection. Issue 4 (11th November 2019)

• Record Type: Journal Article
• Authors: Shen, Yinzhong; Liu, Tingyi; Chen, Jun; Li, Xin; Liu, Li; Shen, Jiayin; Wang, Jiangrong; Zhang, Renfang; Sun, Meiyan; Wang, Zhenyan; Song, Wei; Qi, Tangkai; Tang, Yang; Meng, Xianmin; Zhang, Lijun; Ho, Dean; Ho, Chih‐Ming; Ding, Xianting; Lu, Hong‐Zhou
• Is Part Of: Advanced therapeutics. Volume 3:Issue 4(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2019-11-11
• Subjects: artificial intelligence -- drug therapy -- human immunodeficiency virus; Therapeutics -- Periodicals; Pharmaceutical technology -- Periodicals; Pharmacogenetics -- Periodicals; 615.5
• DOI: 10.1002/adtp.201900114
• Languages: English
• ISSNs: 2366-3987

Abstract

Abstract: Antiretroviral therapy (ART) serves as a mainstay in treating human immunodeficiency virus (HIV) infection. An HIV patient is traditionally administered the same ART regimen for life, even if his/her viral load has been reduced by several orders of magnitude from the initial viral load. Dose reduction in ART has been clinically explored in a trial‐and‐error manner to reduce side effects and improve ART sustainability. Using artificial intelligence (AI), we have discovered that drugs and doses inputs can be related to viral load reduction through a Parabolic Response Surface (PRS). The AI‐PRS platform can rationally guide a clinically‐actionable approach to identify optimized population‐wide and personalized dosing. In this prospective pilot clinical trial, a combination regimen of tenofovir (TDF), efavirenz (EFV) and lamivudine (3TC) is administered to ten patients. Using AI‐PRS, a 33% reduction in the long‐term TDF maintenance dose (200 mg) is identified compared to standard regimens (300 mg). This regimen keeps the HIV viral load below 40 copies/mL with no relapse during a 144‐week observation period. This study demonstrates that AI‐PRS can potentially serve as a scalable approach to optimize and sustain the long‐term management of HIV as well as a broad spectrum of other indications. Abstract : Lifetime antiretroviral therapy (ART) is crucial for HIV/AIDS patients. To find a balance between the ART side effects and the risk of relapse, this prospective pilot clinical study harnesses the parabolic response surface, an artificial intelligence platform, to identify a personalized optimal ART dose. With it, all patients get viral suppression with no relapse during a 144‐week observation period.